10-Q: Imunon Narrows Loss, Advances Ovarian Cancer Drug

Imunon reported a reduced net loss and positive clinical data for its lead ovarian cancer immunotherapy, IMNN-001, while addressing significant going concern and Nasdaq listing challenges.

Summary

• Net loss for the six months ended June 30, 2025, was $6.8 million, an improvement from $9.7 million for the same period in 2024.
• Cash and cash equivalents stood at $4.7 million as of June 30, 2025, down from $5.9 million at December 31, 2024.
• The company has incurred cumulative net losses of approximately $414 million since inception.
• Research and development expenses decreased by 44.5% to $3.4 million for the six months ended June 30, 2025, compared to $6.1 million in the prior year.
• General and administrative expenses decreased by 10.0% to $3.5 million for the six months ended June 30, 2025, compared to $3.9 million in the prior year.
• Positive topline results from the Phase II OVATION 2 Study for IMNN-001 in advanced ovarian cancer showed an 11.1-month increase in median Overall Survival (OS) in the ITT population and a 15.7-month increase in the per-protocol population.
• The FDA has aligned with the protocol for the Phase III pivotal trial (OVATION 3) for IMNN-001, with trial site initiation underway.
• Phase I clinical trial results for the IMNN-101 COVID-19 booster vaccine demonstrated safety, tolerability, and durability of protection with persistent increases in neutralizing antibody titers.
• The company faces substantial doubt about its ability to continue as a going concern due to recurring losses and insufficient capital for the next twelve months.
• Imunon is addressing Nasdaq listing deficiencies, including minimum bid price and stockholders' equity, through a 15-for-1 reverse stock split and a hearing request.
• The company raised approximately $14.0 million in net proceeds from equity sales during 2025 and 2024 through the filing date.

Sentiment

Score: 6

Explanation: The company reported a reduced net loss and significantly improved cash burn from operations, alongside compelling positive clinical data for its lead ovarian cancer program (IMNN-001) and promising early data for its COVID-19 vaccine candidate (IMNN-101). The FDA's alignment on the Phase 3 protocol for IMNN-001 is a major positive. However, these clinical advancements are overshadowed by the explicit 'going concern' warning and the immediate threat of Nasdaq delisting due to both minimum bid price and stockholders' equity deficiencies, which necessitate significant and potentially dilutive capital raises. The recent reverse stock split and stock dividend are attempts to address these issues but highlight the precarious financial position.

Positives

• Net loss significantly decreased to $6.8 million for the six months ended June 30, 2025, from $9.7 million in the same period of 2024.
• Net cash used in operating activities decreased to $5.8 million for the six months ended June 30, 2025, from $10.4 million in the same period of 2024.
• Research and development expenses decreased by 44.5% to $3.4 million for the six months ended June 30, 2025, reflecting reduced spending on certain programs.
• IMNN-001 Phase II OVATION 2 Study showed positive topline results, including an 11.1-month increase in median Overall Survival (OS) in the ITT population and a 15.7-month increase in the per-protocol population.
• IMNN-001 demonstrated a hazard ratio of 0.74 (35% survival improvement) in the ITT population and 0.64 (56% survival improvement) in the per-protocol population.
• For patients treated with a PARP inhibitor, the hazard ratio for IMNN-001 decreased further to 0.41, with median OS not yet reached after over 5 years, compared to 37 months in the standard-of-care arm.
• IMNN-001 treatment resulted in a 13-month increase in median OS (46 vs. 33 months) and a 3-month increase in median PFS (14.9 vs. 11.9 months) compared to standard of care alone.
• IMNN-001 showed a doubling of the CRS 3 chemotherapy response score (26.1% vs. 13.0%) and a higher surgical response rate (64.6% vs. 52.1%).
• The FDA has aligned with the protocol for the Phase III pivotal trial (OVATION 3) for IMNN-001, supporting its advancement.
• The FDA agreed that the company's potency assay for IMNN-001 (measuring interferon-gamma) is acceptable for Phase 3 and commercial use.
• IMNN-101 Phase I clinical trial demonstrated safety, tolerability, and durability of protection for up to six months after a single dose, with up to a 3-fold median increase in neutralizing antibody titers.
• IMNN-101 showed cross-reactivity against the XBB1.5 variant and many newer variants.
• Shareholders approved an increase in authorized common stock from 112.5 million to 350 million shares, providing flexibility for future capital raises.

Negatives

• The company has incurred substantial operating losses since inception, with a cumulative net loss of approximately $414 million as of June 30, 2025.
• The company had only $4.7 million in cash and cash equivalents as of June 30, 2025, which is not expected to be sufficient to fund operations for the next twelve months.
• Management has determined there is substantial doubt regarding the company's ability to continue as a going concern.
• The company received a delisting notice from Nasdaq on May 28, 2025, for failing to meet the minimum bid price requirement ($1.00) and the minimum stockholders' equity requirement ($2.5 million).
• Investment income decreased significantly to $70,000 for the six months ended June 30, 2025, from $307,000 in the prior year, primarily due to a lower cash balance.
• The company's ability to raise additional capital may be adversely impacted by worsening global economic conditions and financial market volatility.
• The 15-for-1 reverse stock split, while intended to regain Nasdaq compliance, significantly reduces the number of outstanding shares and can be perceived negatively by investors.
• The company's stock is subject to risks related to short selling and market making activities, which could depress its price.

Risks

• **Going Concern Uncertainty**: The company has incurred substantial operating losses and negative cash flows, with current capital not expected to be sufficient for the next twelve months, raising substantial doubt about its ability to continue as a going concern.
• **Capital Raising Risk**: The company will need to raise significant additional capital to fund future operations, and there is no assurance that funding will be available on acceptable terms, or at all, potentially leading to significant dilution or relinquishing rights to drug candidates.
• **Nasdaq Delisting Risk**: The company received delisting notices from Nasdaq for failing to meet the minimum bid price ($1.00) and stockholders' equity ($2.5 million) requirements, and there is no assurance that the Nasdaq Hearings Panel will grant its request for continued listing.
• **Drug Development Uncertainty**: Drug research and development is inherently uncertain, with a high risk of failure at every stage, and the timing and outcome of clinical results are difficult to predict.
• **Competition**: The company operates in a highly competitive, highly regulated, and rapidly changing environment, with potential for competitive drug candidates to impact its commercial potential.
• **Intellectual Property Risk**: Risks relating to intellectual property, including prosecuting and enforcing patent claims.
• **Market Price Volatility**: Volatility in the market price of the common stock, potentially exacerbated by short selling.
• **Reliance on Third Parties**: Risks relating to third parties' conduct of clinical trials and the ability to maintain and establish new research and development and licensing arrangements.
• **Regulatory Approvals**: Ability to obtain or maintain U.S. Food and Drug Administration (FDA) and foreign regulatory approvals for drug candidates.
• **Patient Enrollment**: Ability to enroll patients in clinical trials.
• **Reimbursement Risk**: Risks relating to government, private health insurers, and other third-party payers' coverage or reimbursement.
• **Global Economic Conditions**: Potential adverse impact from worsening global economic conditions, tariff announcements, and geopolitical unrest (Russian invasion of Ukraine, Middle East unrest).

Future Outlook

The company plans to continue leveraging its TheraPlas and PlaCCine modalities to advance plasmid DNA technology. It intends to advance IMNN-001 into a Phase III pivotal study (OVATION 3) for advanced ovarian cancer, with trial site initiation and patient enrollment underway. The company plans to submit the OVATION 2 study results for publication in a peer-reviewed medical journal. It will continue to evaluate IMNN-001 in combination with bevacizumab in a Phase I/II study for advanced ovarian cancer, with SLL data expected within one year of enrollment completion and final PFS data in approximately three years. The company intends to seek partnership and/or business development opportunities to develop the scientific and business case for IMNN-101 as a future vaccine to address viral mutations. Management plans to address additional funding requirements by assessing current expenditures, reducing spending, pursuing additional capital funding through equity sales and/or debt facilities, pursuing possible partnerships and collaborations, and potential out-licensing for drug candidates. The company will continue to look for government-sponsored research collaborations and grants to help offset future anticipated losses.

Management Comments

• Our future financial condition and results of operations, as well as any forward-looking statements, are subject to inherent risks and uncertainties, including, but not limited to, the inherent uncertainty in the drug development process, our ability to raise additional capital to fund our planned future operations, our ability to obtain or maintain U.S. Food and Drug Administration (FDA) and foreign regulatory approvals for our drug candidates, our ability to enroll patients in our clinical trials, risks relating to third parties conduct of our clinical trials, risks relating to government, private health insurers and other third-party payers coverage or reimbursement, risks relating to commercial potential of a drug candidate in development, changes in technologies for the treatment of cancer, impact of development of competitive drug candidates by others, risks relating to intellectual property, volatility in the market price of our common stock, potential inability to maintain compliance with The Nasdaq Marketplace Rules and the impact of adverse capital and credit market conditions.
• A fundamental component of the ability to continue as a going concern is the Company’s ability to raise capital as required, as to which no assurances can be provided.
• If management is unsuccessful in these efforts, the Company’s current capital is not expected to be sufficient to fund operations for the next twelve months.
• The Company may not be able to obtain funding on acceptable terms, or at all. The terms of any financing may adversely affect the holdings or the rights of the Company’s stockholders.
• The Company’s ability to raise additional funds will depend, among other factors, on financial, economic and market conditions, many of which are outside of its control, and it may be unable to raise financing when needed, or on terms favorable to the Company.
• If the Company is unable to obtain sufficient capital to fund its operations it may be required to evaluate alternatives.
• We believe that our non-viral DNA technology may be a viable alternative to current approaches to gene delivery due to several distinguishing characteristics, including enhanced molecular versatility that allows for complex modifications to potentially improve activity and safety.
• We believe that these advantages place Imunon in a position to capitalize on this technology platform.
• Imunon’s vaccine approach is designed to optimize the quality of the immune response dictating the efficiency of pathogen clearance and patient recovery.
• We believe the adaptation of our TheraPlas technology, PLACCINE, has the potential to meet these challenges [of viral mutations, efficient manufacturing, distribution, and storage].

Industry Context

The company operates in the highly competitive and regulated biotechnology sector, specifically focusing on oncology (ovarian cancer) and infectious diseases (COVID-19 vaccines). Its TheraPlas modality for solid tumors leverages an immunological approach, aligning with the growing trend of immunotherapy in cancer treatment, particularly for difficult-to-treat cancers like advanced ovarian cancer where traditional therapies have limited success. The focus on IL-12 and IFN-gamma aligns with established cytokine-based immunotherapies. The PlaCCine DNA vaccine modality addresses the urgent need for new vaccine technologies, especially for emerging pathogens and rapidly mutating viruses like SARS-CoV-2, by offering a flexible, non-viral platform with potential for broad-spectrum protection and improved stability compared to some current vaccine technologies. The company's strategy to seek partnerships and collaborations for its vaccine program is common in the biotech industry to de-risk and accelerate development and commercialization, especially for large-scale public health needs.

Comparison to Industry Standards

• **Ovarian Cancer (IMNN-001)**: IMNN-001's median PFS of 21 months (OVATION 1, per protocol) and 18.4 months (ITT) significantly exceeds the average 12-month progression-free period for women with Stage III/IV ovarian cancer undergoing neoadjuvant chemotherapy (NACT) under current standard of care.
• The 13-month increase in median OS (46 vs. 33 months) and 3-month increase in median PFS (14.9 vs. 11.9 months) in the OVATION 2 Study for IMNN-001 compared to standard of care alone demonstrates a substantial improvement over existing treatments. For comparison, approved second-line therapies for platinum-resistant ovarian cancer, such as pegylated liposomal doxorubicin, topotecan, and bevacizumab, typically show overall response rates of 10% to 20% with median overall survival (OS) of 11 to 12 months. IMNN-001's results are notably superior.
• The hazard ratio of 0.41 in the PARP inhibitor subgroup, with median OS not yet reached after >5 years, suggests a strong synergistic effect, potentially outperforming the 37-month median OS observed with standard PARP inhibitor maintenance therapy alone.
• **COVID-19 Vaccine (IMNN-101)**: Preclinical results demonstrated comparable protection efficiency (>95%) to a commercial mRNA vaccine in non-human primates, indicating its potential to match the efficacy of leading approved vaccines.
• The observed stability of PLACCINE at storage temperatures of 4°C to 25°C offers a significant logistical advantage over many commercial mRNA vaccines that require ultra-cold chain storage, making it more adaptable for global distribution.
• The durability of protection at six months after a single dose and cross-reactivity against multiple variants, including XBB1.5, positions IMNN-101 as a competitive candidate for seasonal booster vaccines, potentially offering broader and more sustained immunity than some current single-variant or less durable options.

Corporate Governance

Legal Proceedings

• Not currently a party to any material legal proceedings.

Stakeholder Impact

• **Shareholders**: Significant dilution from recent and planned equity financings; potential for further dilution from stock incentive plans and warrants; risk of delisting from Nasdaq impacting liquidity and value; potential for increased share price due to reverse stock split; receipt of stock dividend.
• **Patients**: Potential for new, effective treatments for advanced ovarian cancer (IMNN-001) and improved COVID-19 vaccines (IMNN-101) if clinical development is successful.
• **Employees**: Stock-based compensation plans provide incentives; continued employment depends on the company's ability to secure funding and continue as a going concern.
• **Creditors**: Risk associated with the company's 'going concern' uncertainty and reliance on future capital raises.
• **Regulatory Authorities**: Ongoing engagement with FDA for clinical trial approvals and manufacturing alignment.

Next Steps

• Initiate trial sites and begin enrolling study participants for the Phase III OVATION 3 trial for IMNN-001 in advanced ovarian cancer.
• Submit the results of the OVATION 2 Study for publication in a peer-reviewed medical journal.
• Continue patient enrollment in the Phase I/II study evaluating IMNN-001 in combination with bevacizumab in advanced ovarian cancer.
• Seek partnership and/or business development opportunities for IMNN-101 as a future vaccine.
• Pursue additional capital funding in public and private markets through equity sales and/or debt facilities.
• Pursue possible partnerships and collaborations and potential out-licensing for drug candidates.
• Continue efforts to regain and maintain compliance with Nasdaq listing standards, including the minimum bid price and stockholders' equity requirements.
• Evaluate the impact of the One Big Beautiful Bill Act (OBBBA) on income tax disclosures.
• Present IMNN-101 Phase 1 clinical trial results at the 10th International Conference on Vaccines Research & Development in November 2025.

Key Dates

Recommendation

Imunon presents a high-risk, high-reward profile. The positive Phase II clinical data for IMNN-001 in advanced ovarian cancer, including significant improvements in overall survival and progression-free survival, and the FDA's alignment on the Phase III protocol, are substantial positive developments that could drive long-term value. Similarly, the promising Phase I data for the IMNN-101 COVID-19 vaccine platform suggests broader potential. However, these clinical successes are currently overshadowed by severe financial distress, including a 'going concern' warning and imminent Nasdaq delisting due to both minimum bid price and stockholders' equity deficiencies. While the company is actively raising capital and implementing corporate actions like a reverse stock split to address these issues, the success of these efforts and the ability to secure sufficient long-term funding remain highly uncertain. For a seasoned investor, the clinical progress warrants continued observation, but the significant financial and listing risks suggest a 'hold' rather than a 'buy' or 'sell' at this juncture, pending clearer resolution of its liquidity and listing status. A 'strong buy' would be premature given the financial instability, and a 'sell' would disregard the compelling clinical advancements.

Keywords

Biotechnology, Ovarian Cancer, Immunotherapy, DNA Vaccine, Clinical Stage, IMNN-001, OVATION Study, IMNN-101, COVID-19 Vaccine, TheraPlas, PlaCCine, Nasdaq Listing, Going Concern, SEC Filing, Drug Development, Oncology, Vaccines